The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
